抑癌基因p53结合蛋白1基因突变与前列腺腺癌的关系

Correlation of 53BP1 gene mutation with prostatic adenocarcinoma

目的检测抑癌基因p53结合蛋白1（53BP1）基因突变在前列腺腺癌和良性前列腺增生组织中的发生率，分析53BP1基因突变与前列腺腺癌的相关性。方法采用基因组DNA抽提、聚合酶链反应（PCR）扩增及基因测序的方法检测50例前列腺腺癌与10例良性前列腺增生组织中53BPl基因的突变情况。结果50例前列腺腺癌组织中共检测到15种不同类型的53BPl基因异常，其中4种为正常组织中也检测到的单核苷酸多态性，11种不同类型的突变发生在12例前列腺腺癌组织中，总突变率达24．0％（12／50）。11种53BP1基因突变中，7种为错义突变，但均未发生在重要结构域上，另外4种为同义突变，其中C．4760G〉T突变位于53BP1Tudor结构域。53BP1基因突变与前列腺腺癌患者多种临床病理参数均无明显相关性（P〉0．05）。结论对前列腺腺癌患者的53BP1基因全长外显子进行突变检测发现有一定比例的基因突变，推测53BP1基因突变与前列腺腺癌的发生有关。

Objective To study the incidence of 53BP1 gene mutations in prostatic adenocarcinoma and benign prostatic hypertrophy, and to analyze the relationship between 53BP1 mutations and prostatic adenocarcinoma. Methods Genomic DNA extraction, PCR amplification and gene sequencing were used to detect the occurrence of 53BP1 gene mutations in 50 cases of prostatic adenocareinoma. Ten cases of benign prostatic hypertrophy were included as controls. Results Amongst the 50 eases of prostatic adenocarcinoma studied, 15 showed genetic alterations of 53BP1, including 4 cases with single nucleotide polymorphism. The mutation rate was 24.0% （12/50）. Seven of the 53BP1 mutations detected represented missense mutations and none of them were situated in functionally important domains. The other 4 were synonymous mutations, in which c. 4760G 〉 T was situated in Tudor domain. There was no obvious correlation between 53BP1 gene mutations and the various clinicopathologic parameters of prostate adenocarcinoma（ P 〉 0. 05 ）. Conclusion Certain percentage of prostatic adenocarcinoma harbors 53BP1 mutations which may be involved in the carcinogenesis.